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Background Due to increased morbidity and mortality, prosthetic valve infective endocarditis (IE) with dehiscence requires ur-
gent intervention. Early identification and therapy may prevent embolization.
...................................................................................................................................................................................................
Case summary A 27-year-old Caucasian woman with a history of hepatitis C, intravenous drug abuse, and tricuspid valve (TV) re-
placement was admitted for recurrent IE. She was found to have bacteraemia and fungaemia, and empiric antibiot-
ics were initiated. Transthoracic echocardiogram (TTE) revealed a mobile ‘mass’ on the TV and dehiscence. The
patient developed cardiogenic shock and repeat TTE showed a ruptured TV and absence of the ‘mass’, suspicious
of embolization. She underwent emergent surgery with TV replacement using a Biocor valve and retrieval of the
old CorMatrix valve found in the right mid pulmonary artery (PA). The patient was successfully weaned off ino-
tropic agents and completed a prolonged course of antibiotics and anti-fungals.
...................................................................................................................................................................................................
Discussion The multi-disciplinary decision on timing of surgical intervention was challenging, especially due to ongoing myco-
bacterial infection that increased operative risk. With clinical deterioration, urgent surgery was performed revealing
an embolized prosthetic valve in the PA. New surgical options for TV replacement in IE with extracellular-based
material have shown promising outcomes with little reported data of long term complications. This case demon-
strates a rare occurrence of embolized CorMatrix TV and highlights the challenge in timing of appropriate surgical
intervention in a septic patient with thrombocytopenia.
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Introduction
Tricuspid valve replacement (TVR) secondary to infective endocardi-
tis (IE) is challenging with high rates of complications and mortality.
Intravenous drug use (IVDU), instrumentation such as peripherally
inserted central catheter, and long-term central venous catheter lines
are pre-disposing factors for right sided endocarditis. Common sites
of embolization include the pulmonary system causing either an infec-
tion or a clot. In the setting of an inter-atrial shunt, embolic strokes
Learning points
• Surgical options for tricuspid valve replacement (TVR) with
extracellular-based material have shown promising outcomes
with little reported data of long-term complications.
• Surveillance blood cultures should be obtained in high-risk
patients and rapid surgical intervention, involving a multi-discip-
linary team should be considered despite sepsis.
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..are rare. The literature has demonstrated excellent outcomes from
the extracellular-based material (ECM) CorMatrix valve,1 however,
long-term data is lacking. To the best of our knowledge, this is the
first reported case of an infected CorMatrix TV that embolized to
the pulmonary artery (PA).
Timeline
Case presentation
A 27-year-old Caucasian woman with hepatitis C (HCV), current
IVDU, and TVR was transferred to our institution for IE due to sur-
veillance blood cultures yielding Candida parapsilosis and
Staphylococcus. Three months prior to this admission, she had com-
pleted a 6-week course of antibiotics, followed by TVR with a
CorMatrix valve for endocarditis. Post-operative complications
included pulmonary embolism (PE) treated with coumadin. Prior to
3 months prior to admission History of intravenous drug use
Tricuspid valve (TV) endocarditis and bacteraemia (Candida and Staphylococcus aureus) treated with 6 weeks of IV
antibiotics and anti-fungals (vancomycin, daptomycin, linezolid, cefepime, and micafungin). TV replaced with
CorMatrix extracellular-based material. Post-operative complications of pulmonary embolism, Coumadin was
therefore initiated
Admission day Patient informed about surveillance blood cultures returning positive for methicillin-sensitive S. aureus and Candida
parapsilosis
Returned to hospital where patient had complaints of gingival haemorrhage, spontaneous bruising, and abdominal
swelling
Labs showed supratherapeutic international normalized ratio (INR) >10 and thrombocytopenia (12  109 lL)
Computed tomography abdomen and pelvis showed large pericardial effusion and hepatosplenomegaly with mild
ascites
Infectious disease consulted with recommendations to start nafcillin and amphotericin B. Blood cultures repeated
Admitted to the Cardiology Intermediate Unit at our institution
Day 1 of admission Echocardiogram shows large mobile mass involving the TV that prolapses into the right atrium, causing possibly flail
and dehisced TV. Very large pericardial effusion (4.21 cm posteriorly and 3.73 cm anteriorly) with evidence of
markedly elevated intrapericardial pressure causing diastolic compression of the right ventricle (RV)
Day 1 of admission Ultrasound-guided pericardiocentesis with removal of 600 mL of serous fluid
Echocardiogram showed residual moderate effusion with no right ventricular diastolic collapse
Nafcillin switched to cefazolin and continued on amphotericin B
Day 3 of admission Blood cultures from 02/13 return positive for Mycobacteria in 2/4 bottles. Repeat blood cultures obtained
Amphotericin B discontinued and switched to fluconazole
Echocardiogram shows severe TV thickening and large vegetation is pedunculated and mobile. Ruptured TV
chordae with a flail septal leaflet. Effusion measures 2.8 cm anteriorly and 3.8cm posteriorly. Some evidence of
right ventricular compression without collapse
Day 7 of admission Blood cultures from 02/18 return positive for C. parapsilosis
Clinical deterioration with tachycardia, increased dyspnoea, abdominal distension, lower extremity oedema,
persistent fevers, and lactic acid at nine. Transferred to the CICU
Echocardiogram shows severe ‘torrential’ wide open tricuspid regurgitation, flail septal leaflet of TV with
echodensity attached to tip suggestive of ruptured chordae and/or vegetation. When compared with prior
transthoracic echocardiogram on 02/18, large vegetation attached to tricuspid leaflet is no longer
visualized—suspicious for embolization
Cefazolin and fluconazole switched to liposomal amphotericin B, amikacin, imipenem, and azithromycin
Day 7 of admission Continued clinical deterioration (tachypneic, hypoxic, and hypotensive) requiring intubation and pressors
Day 8 of admission Continued clinical decline with severe metabolic acidosis (lactic acid of 19, pH of 7.27) and signs of multiorgan
failure
Taken to the OR for emergent TVR by Cardiothoracic Surgery
Emergency redo sternotomy, redo TV replacement with 29 Biocor valve, removal of embolized old CorMatrix TV
from right pulmonary artery
Day 9 of admission Blood cultures from 02/19 return positive for Mycobacterium
Switched amphotericin B to micafungin and continued on amikacin, imipenem, and azithromycin. Recommendations
were to complete micafungin for a total of 6 weeks and antibiotics for a total of 3 months
Day 28 of admission Patient discharged home





















arrival, levofloxacin, piperacillin-tazobactam, vancomycin, nafcillin,
and amphotericin B were initiated. A computed tomography (CT)
scan of her abdomen and pelvis revealed a pericardial effusion, mild
hepatosplenomegaly, and anasarca. She was afebrile, with a blood
pressure of 131/70 mmHg and heart rate of 90 b.p.m. Cardiovascular
exam was remarkable for grade 2/6 holosystolic murmur at the left
lower sternal border and jugular venous distention (JVD) to her ears.
She had a distended abdomen and 3þ pitting oedema in bilateral
lower extremities extending to her knees. Complete blood count
showed normal white count, platelet count of 12 109/L (normal
range 150 000–450 000 109/L), normocytic anaemia with haemo-
globin of 9.7 g/dL (normal range 12–16 g/dL), and an international
normalized ratio (INR) >10 (normal rage of 1.0–2.0) reversed with
IV vitamin K and discontinuation of coumadin. Erythrocyte sedimen-
tation rate (ESR) was 27 mm/h (normal range 0–23 mm/h), fibrinogen
was 140 mg/dL (normal range 200–400 mg/dL). Aspartate transamin-
ase (AST) was 55 U/L and ALT - alanine transaminase was 20 U/L
(normal range are 10–31 U/L and 10–41 U/L, respectively).
Peripheral blood smear revealed numerous schistocytes and rare
large platelets. Transthoracic echocardiogram (TTE) showed a mo-
bile mass involving the TV with a large pericardial effusion measuring
4.21 cm by 3.73 cm. There was also evidence of elevated intrapericar-
dial pressure causing diastolic compression of the right ventricle (RV)
(Figure 1A, Supplementary material online, Videos S1A, B, S2A, B, S3A,
B). Removal of 600 mL of serous pericardial fluid returned negative
for bacteria, fungi, and viruses. Analysis was consistent with an exuda-
tive effusion. There was no apparent abscess or paravalvular leak.
Repeat TTE following pericardiocentesis showed reduced pericardial
effusion with relief of RV compression. On Day 8, she developed car-
diogenic shock with worsening metabolic acidosis despite vasopres-
sors that were started the day before. TTE showed torrential
tricuspid regurgitation (TR) with a filling defect in the right PA (Figure
1B, Supplementary material online, Video S4A, B). Left ventricular
function was normal but the RV was dilated and poorly functional.
There was an attempt to perform CT chest, however, due to haemo-
dynamic instability, she underwent emergent surgery. Several units of
platelets, fresh frozen plasma, and packed red blood cells were
required during surgery. The TV was replaced using a Biocor valve
(Figure 1C, Supplementary material online, Video S5) following re-
trieval of the CorMatrix valve from the PA. Pathology of the
extracted valve showed acutely inflamed tissue with bacteria, fungal
element and acid-fast bacilli. She was discharged home on a pro-
longed course of antibiotics with Linezolid, Amikacin and Micafungin.
All her laboratory values improved. Upon discharge, the patient
moved out of state, however, was re-admitted within 2 months for
blood cultures positive for AFB. TEE revealed new TV vegetations.
Due to recurrent IVDU, she was not a candidate for surgical inter-
vention and was treated with 6 weeks of Linezolid and Imipenem.
The patient has since been lost to follow-up.
Discussion
This case presents several important points including the challenges
of TVR, need for additional long-term data on ECM in endocarditis
and multi-disciplinary management of recurrent IE in high-risk
patients. The patient’s presentation raised several differential
diagnoses. Anasarca and JVD was thought to be due to portal hyper-
tension from hepatic disease vs. right sided heart failure (HF). Liver
disorder was unlikely as the CT of the abdomen did not reveal any
portal vein thrombosis, cirrhosis, or oesophageal varices and HCV
load was mildly elevated but not higher than previous levels. Her
presentation was likely secondary to decreased RV function with TR
seen on TTE. Thrombocytopenia was multifactorial from sepsis-
related disseminated intravascular coagulation and myelosuppression
from antibiotic use. Due to creatinine levels being at baseline and
Figure 1 (A) Two-dimensional transthoracic echocardiogram of
the right ventricular inflow view depicting a large mobile vegetation/
mass (arrow) attached to the tricuspid valve leaflet. (B) Two-dimen-
sional transthoracic echocardiogram of the right ventricular inflow
view illustrating an absence of vegetation/mass and dehisced tricus-
pid valve (asterisk) with a large pericardial effusion. (C) Two-dimen-
sional transthoracic echocardiogram of the right ventricular inflow
view demonstrating a replaced prosthetic tricuspid valve (asterisk).
PE, pericardial effusion; RA, right atrium; RV, right ventricle.






































..normal neurological status, thrombotic thrombocytopenic purpura,
and haemolytic uremic syndrome were unlikely. The presentation of
acute right sided HF with anasarca, JVD, supratherapeutic INR, and
thrombocytopenia was due to recurrent polymicrobial bacteraemia
and IE, in the setting of a PE on coumadin.
TV endocarditis is a known complication of IVDU. Morbidity and
mortality rates (1% to 6%) are higher in patients with replaced or
repaired TV and recurrent endocarditis.2,3 The causative organism
has a major role with Staphylococci carrying an increased mortality
rate.3 Management is multidisciplinary often involving cardiology, car-
diothoracic surgery, infectious disease and in certain situations, critic-
al care medicine. Early surgical intervention is indicated in
haemodynamic instability, septic embolism, uncontrolled infection
and IE caused by Staphylococci, fungi, Coxiella, and Chlamydia.4 Early
surgery results in lower rates of recurrence and nearly 90% chance
of survival.5 However, in the setting of active infection, surgery should
be delayed due to higher operative complications.2
Due to the unique anatomy of the TV and associated risks with
bioprosthetic and mechanical valves, there are no ideal prostheses
designed for replacement.6 The fragility of the leaflet tissue and prox-
imity of the right coronary artery to the TV and annulus renders the
procedure particularly challenging.7 In comparison, the mitral valve
(MV) is anatomically closer to the left ventricular outflow tract and
the aortic valve, which also causes limitations, but the durability of
the MV annulus decreases the risk of complications.8 Technology in
both valvular procedures has advanced with the CorMatrix valve for
the TV and the transcatheter approach for the MV. Multimodality
imaging tools are often used to measure the annulus size in order to
minimize complications.
The successful management of TV endocarditis includes the exci-
sion of all infected tissue without valve replacement, but this is often
complicated by the development of TR, which cannot be tolerated in
up to 25% of patients.9 In the absence of guidelines, the current best
approach is monitoring high risk patients through blood culture sur-
veillance. If there is concern for recurrent IVDU, it is reasonable to
obtain blood cultures more frequently.
The CorMatrix ECM derived from porcine small intestines func-
tions as an acellular bioscaffold allowing for native integration of the
valve and tissue regeneration. It has garnered increasing interest for
use in valve replacement as it eliminates the need for chronic anticoa-
gulation therapy and reduces the risk of valve calcification and recur-
rent infection.10 In the adult population, the utility of ECM in valve
....................................................................................................................................................................................................................
Table 1 Summary of current literature on CorMatrix ECM for valvular repair
Study Study type Valve Indication Patient
population
Follow-up Results
Gerdisch et al.1 Prospective Tricuspid TV endocarditis 19 1–18 month
echocardiogram
One patient had recurrent disruption of
implant at 13 and 22 months
One patient had fungal infection
Remaining had functioning TV and stable left
and right systolic function at 18 months
Gerdisch et al.16 Prospective Mitral Endocarditis,
MR, MS
19 4 days to 48 months
(median 10.8 months)
echocardiogram
Three deaths were unrelated to MR
Two patients had reintervention unre-
lated to MR
Remaining had functioning MV at follow-up
Kelley et al.14 Retrospective Mitral MR 44 Histology (if re-operated)
3, 6, and 12 month
echocardiogram
Eight patients had severe MR (one central
perforation, five enlargement with re-
dundancy, and one dehiscence at suture
line)
Fifteen patients had functioning MV at 1-
year follow-up
Wallen et al.12 Case report Tricuspid TV endocarditis 1 3 month echocardiogram Mild residual TR
Improved RV functioning
Luk et al.15 Case series Mitral MV endocarditis 2 10–18 months
echocardiogram
One patient had severe MR secondary to
perforated AML at 10 months follow-up
Two patients had bacteraemia and recur-
rent endocarditis secondary to perfo-
rated AML at 18 month follow-up
Sundermann
et al.11
Case report Mitral MV endocarditis 1 34 day echocardiogram Competent MV with no recurrent
endocarditis
Current literature available identified two prospective, one retrospective, two case reports and one case series of the ECM CorMatrix valve for endocarditis, mitral regurgita-
tion (MR), and mitral stenosis (MS).
AML, anterior mitral leaflet; ECM, extracellular-based material; MS, mitral stenosis; MR, mitral regurgitation; MV, mitral valve; RV, right ventricle; TV, tricuspid valve.








































































..replacement is limited to case reports and small prospective studies
(Table 1). Favourable results have been seen at 18-month follow up1
and others have shown resolution of symptoms with CorMatrix
ECM intracardiac structural repair in the setting of endocarditis11,12
however, long-term outcomes are lacking.
CorMatrix ECM naturalization occurs via an inflammatory re-
sponse leading to fibrin deposition, which is subsequently replaced by
smooth muscle and endothelial cells. In our patient, inadequate timing
for regeneration vs. intense inflammation in the setting of persistent
infection, may have predisposed the valve to damage and dehiscence.
Contrary to the manufacturer’s claim, there are reports of adverse
effects involving inflammation of the CorMatrix valve. Inflammation,
fibrosis, neovascularization, and necrosis were observed in 12
explanted CorMatrix specimens with little to no evidence of
remodelling12 and in another study, no resemblance to the native
valve at 9 months.13 Among 44 patients who had MV repair using
CorMatrix ECM, 32% had recurrence of severe mitral regurgitation
as a result of patch failure.14 It is therefore possible that inflammation
may play a role in failure however, mechanisms still need to be fur-
ther elucidated.
Conclusion
Given the risk for dire complications in delayed intervention, close
monitoring of patients with IE after TVR is crucial, especially in on-
going IVDU. Despite promising results with CorMatrix valves, recur-
rent TV IE increases mortality and morbidity. Timing of surgical
intervention should involve multidisciplinary evaluation and discus-
sion, however, in the setting of cardiogenic shock, emergent TVR is
necessary.
Supplementary material
Supplementary material is available at European Heart Journal - Case
Reports online.
Consent: The author/s confirm that written consent for
submission and publication of this case report including image(s) and
associated text has been obtained from the patient in line with COPE
guidance.
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